Abstract
Linear FGF receptor-binding heptapeptides were identified by phage display using sequential rounds of biopanning against cells with displacement of phage by FGF2. The consensus motif MXXP was iterated after four to five rounds and the peptide MQLPLAT was studied in depth. Phage bearing MQLPLAT showed high levels of binding to FGF receptor positive cells, with over 90% of phage bound being eluted competitively by adding free FGF2. MQLPLAT phage showed only limited binding to Cos7 cells deficient in receptors for FGF. MQLPLAT phage bound to SKOV3 cells with a Kd of 2.51×10−10 M. Although binding could be blocked by preincubation with free FGF2, heparin could not displace the phage. Use of MQLPLAT to target polyelectrolyte gene delivery vectors in vitro in the presence of serum achieved up to 40-fold greater transgene transduction than nontargeted vectors. MQLPLAT phage were administered into gastric carcinomas via the tumor-feeding artery immediately following resection from patients. The phage showed up to 9-fold more accumulation in the tumor than in adjacent regions of normal tissue, whereas control phage showed less than 2-fold. These peptides should provide useful ligands for specific delivery of gene therapy vectors to clinically relevant targets.
Similar content being viewed by others
References
Fisher KD, Stallwood Y, Green NK et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies Gene Ther 2001 8: 341–348
Larocca D, Kassner PD, Witte A et al. Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage FASEB J 1999 13: 727–734
Goldman CK, Rogers BE, Douglas JT et al. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor Cancer Res 1997 57: 1447–1451
Gu DL, Gonzalez AM, Printz MA et al. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice Cancer Res 1999 59: 2608–2614
Kasahara N, Dozy AM, Kan YW . Tissue-specific targeting of retroviral vectors through ligand–receptor interactions Science 1994 266: 1373–1376
Sosnowski BA, Gu DL, D'Andrea M et al. FGF2-targeted adenoviral vectors for systemic and local disease Curr Opin Mol Ther 1999 1: 573–579
Chandler LA, Sosnowski BA, Greenlees L et al. Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines Int J Cancer 1999 81: 451–458
Basilico C, Moscatelli D . The FGF family of growth factors and oncogenes Adv Cancer Res 1992 59: 115–165
Kurokawa T, Sasada R, Iwane M et al. Cloning and expression of cDNA encoding human basic fibroblast growth factor FEBS Lett 1987 213: 189–194
Barry MA, Dower WJ, Johnston SA . Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries Nat Med 1996 2: 299–305
Pasqualini R, Ruoslahti E . Organ targeting in vivo using phage display peptide libraries Nature 1996 380: 364–366
Arap W, Pasqualini R, Ruoslahti E . Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model Science 1998 279: 377–380
Trepel M, Grifman M, Weitzman MD et al. Molecular adaptors for vascular-targeted adenoviral gene delivery Hum Gene Ther 2000 11: 1971–1981
Pasqualini R, Koivunen E, Ruoslahti E . Alpha v integrins as receptors for tumor targeting by circulating ligands Nat Biotechnol 1997 15: 542–546
New England Biolabs Inc. Ph.D-7 Phage Display Peptide Library Kit: Instruction Manual 1999 Version 2.5
Monaci P, Urbanelli L, Fontana L . Phage as gene delivery vectors Curr Opin Mol Ther 2001 3: 159–169
Larocca D, Witte A, Johnson W et al. Targeting bacteriophage to mammalian cell surface receptors for gene delivery Hum Gene Ther 1998 9: 2393–2399
Poul MA, Marks JD . Targeted gene delivery to mammalian cells by filamentous bacteriophage J Mol Biol 1999 288: 203–211
Fallaux FJ, Kranenburg O, Cramer SJ et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1–deleted adenoviral vectors Hum Gene Ther 1996 7: 215–222
Wong JK, Kennedy PR, Belcher SM . Simplified serum- and steroid-free culture conditions for high-throughput viability analysis of primary cultures of cerebellar granule neurons J Neurosci Methods 2001 110: 45–55
Johnston CL, Cox HC, Gomm JJ et al. bFGF and aFGF induce membrane ruffling in breast cancer cells but not in normal breast epithelial cells: FGFR-4 involvement Biochem J 1995 306: 609–616
Ballinger MD, Shyamala V, Forrest LD et al. Semirational design of a potent, artificial agonist of fibroblast growth factor receptors Nat Biotechnol 1999 17: 1199–1204
Baird A, Schubert D, Ling N et al. Receptor- and heparin-binding domains of basic fibroblast growth factor Proc Natl Acad Sci USA 1988 85: 2324–2328
Ray J, Baird A, Gage FH . A 10-amino acid sequence of fibroblast growth factor 2 is sufficient for its mitogenic activity on neural progenitor cells Proc Natl Acad Sci USA 1997 94: 7047–7052
Yayon A, Aviezer D, Safran M et al. Isolation of peptides that inhibit binding of basic fibroblast growth factor to its receptor from a random phage-epitope library Proc Natl Acad Sci USA 1993 90: 10643–10647
McConnell SJ TV, Spinella DG . Isolation of fibroblast growth factor receptor binding sequences using evolved phage libraries Comb Chem High Throughput Screening 1999 2: 155–163
Ornitz DM, Xu J, Colvin JS et al. Receptor specificity of the fibroblast growth factor family J Biol Chem 1996 271: 15292–15297
Ueki T, Koji T, Tamiya S et al. Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinoma J Pathol 1995 177: 353–361
Acknowledgements
We are grateful to The Cancer Research Campaign and Shinshu University Hospital. We thank Dr Mary Keen for invaluable help with estimation of binding affinity, and Dr Richard Dales for critically reading and editing the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maruta, F., Parker, A., Fisher, K. et al. Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Ther 9, 543–552 (2002). https://doi.org/10.1038/sj.cgt.7700470
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700470
- Springer Nature America, Inc.
Keywords
This article is cited by
-
In Vivo Anti-Tumor Effect of Expressing p14ARF-TAT Using a FGF2-Targeted Cationic Lipid Vector
Pharmaceutical Research (2011)
-
Clinical development of gene therapy for colorectal cancer
Nature Reviews Cancer (2003)